These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24220936)

  • 21. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
    Kumar R; Lu SK; Minchom A; Sharp A; Davidson M; Gunapala R; Yap TA; Bhosle J; Popat S; O'Brien ME
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):375-83. PubMed ID: 26706729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
    Ranson M; Reck M; Anthoney A; Hanauske AR; Dean E; Melezinek I; Klingelschmitt G; Kletzl H; Blatter J; Twelves C
    Ann Oncol; 2010 Nov; 21(11):2233-2239. PubMed ID: 20444843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
    Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
    J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlotinib: a new therapeutic approach for non-small cell lung cancer.
    Bonomi P
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1395-401. PubMed ID: 12882624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
    Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer.
    Tournoux-Facon C; Robinet G; Pinel MC; Ferre P; Tourani JM
    Am J Clin Oncol; 2012 Aug; 35(4):378-85. PubMed ID: 22814308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients.
    Tournoux-Facon C; Senellart H; Lemarie E; Tourani JM; Favrel S; Pouget JC; Pinel MC; Bennouna J
    J Thorac Oncol; 2011 Jul; 6(7):1247-53. PubMed ID: 21610520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
    Clément-Duchêne C; Natale RB; Jahan T; Krupitskaya Y; Osarogiagbon R; Sanborn RE; Bernstein ED; Dudek AZ; Latz JE; Shi P; Wakelee HA
    Lung Cancer; 2012 Oct; 78(1):57-62. PubMed ID: 22809813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
    Sangha R; Davies AM; Lara PN; Mack PC; Beckett LA; Hesketh PJ; Lau D; Li T; Perkins N; Gandara DR
    J Thorac Oncol; 2011 Dec; 6(12):2112-9. PubMed ID: 21892109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Ou SI; Govindan R; Eaton KD; Otterson GA; Gutierrez ME; Mita AC; Argiris A; Brega NM; Usari T; Tan W; Ho SN; Robert F
    J Thorac Oncol; 2017 Jan; 12(1):145-151. PubMed ID: 27697581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
    Brahmer JR; Lee JW; Traynor AM; Hidalgo MM; Kolesar JM; Siegfried JM; Guaglianone PP; Patel JD; Keppen MD; Schiller JH
    Eur J Cancer; 2014 Jan; 50(2):302-8. PubMed ID: 24246704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
    Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
    Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
    Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.
    Bhateja P; Dowlati A; Sharma N
    Invest New Drugs; 2018 Jun; 36(3):435-441. PubMed ID: 28971268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
    Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
    Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
    Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Mok TS; Geater SL; Iannotti N; Thongprasert S; Spira A; Smith D; Lee V; Lim WT; Reyderman L; Wang B; Gopalakrishna P; Garzon F; Xu L; Reynolds C
    Ann Oncol; 2014 Aug; 25(8):1578-84. PubMed ID: 24827127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.